Chemoradiation and Panitumumab for Esophageal Cancer
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
A consistent finding in many studies in patients with operable esophageal and
gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy,
particularly the absence of residual disease in the surgical specimen, is an indicator of
better disease-free and overall survival. Therefore in the investigators trial the
investigators will evaluate the pathologic response of panitumumab in combination with
neoadjuvant chemoradiation as first line treatment of operable adenocarcinomas,
undifferentiated or squamous cell carcinomas of the esophagus.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)